

Form PTO-1449

U.S. Department of Commerce  
Patent and Trademark OfficeATTY. DOCKET NO.  
IVD 978-2

SERIAL NO.

**INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT***(Use several sheets if necessary)*APPLICANT  
Maruani et alFILING DATE  
1/11/02

GROUP

 1046 U.S. PTO  
 10/044531  
 01/11/02
**U.S. PATENT DOCUMENTS**

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
	4,707,497	11/17/87	Cecchi et al	514	647	

**FOREIGN PATENT DOCUMENTS**

Document Number	Date	Country	Class	Subclass	Translation Yes   No
EP 0 656 354	06/07/95	EPO			X

**OTHER DOCUMENTS** *(Including Author, Title, Date, Pertinent Pages, Etc.)*

	D. Shire et al., J. Biol. Chem., 271 (12) 1996, pp. 6941-6946
	R. Pertwee et al., Life Sci., 56 (23/24), 1995, pp. 1941-1947
	M. Rinaldi-Carmona et al., Life Sci., 56(23/24), 1995, pp. 1949-1955
	F. Barth et al. NIDA Res. Monograph, 162, 1996, pp. 52-53
	M. Rinaldi-Carmona et al., Life Sci., 58(15), 1996, pp. 1239-1247
	M. Rinadli-Carmona et al., FEBS Letters, 350 (2-3), 1994, pp. 240-244

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Division Under 37 C.F.R. 1.53(b)  
Application of: Maruani et al.

Prior Application Serial No.: 09/341,764

Prior Filing Date: August 19, 1999

Prior Group Art Unit: 1617

Anticipated Classification of this Application:  
Class 514 Subclass 406.000

Examiner: J. Kim

For: USE OF CANNABINOID RECEPTOR  
ANTAGONISTS FOR THE PREPARATION OF  
DRUGS

Commissioner for Patents  
Box Patent Application  
Washington, D.C. 20231

Dear Sir:

CITATION OF REFERENCES

Enclosed herewith on an Information Disclosure Statement by Applicant (Form PTO-1449) is a list of references for consideration by the Examiner.

This Information Disclosure Statement is being filed concurrently with the above-identified application and, consequently, no fee or statement pursuant to 37 C.F.R. §1.97(c) or (d) is required. Furthermore, pursuant to 37 C.F.R. §1.98(d), copies of the listed references are not being provided as they were previously cited by or submitted to the Examiner in prior application Serial No. 09/341,764, filed August 19, 1999, which is relied upon for an earlier filing date under 35 U.S.C. §120.

Respectfully submitted,

Date: January 11, 2002

Address:  
Patent Department  
Sanofi-Synthelabo Inc.  
9 Great Valley Parkway  
Malvern, PA 19355  
Telephone No. (610) 889-8802  
Facsimile: (610) 889-8799

**CERTIFICATE UNDER 37 C.F.R. 1.10**

Express Mail Label Number: EL676470283US

Date of Deposit: January 11, 2002

I hereby certify that this paper is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" Service on the date indicated above and is addressed to: Commissioner for Patents, Box Patent Application, Washington, DC 20231

Signature



11046 U.S. PTO  
10/044531  
01/11/02

